Trials Show New Therapies for Kidney Disease
Researchers presented updated trial data on emerging treatments for glomerular diseases at the American Society of Nephrology's Kidney Week 2026.
Updated on Nov. 16, 2026 in Diseases — General

Dr. Brad Rovin presented updates on emerging therapies for glomerular diseases at the American Society of Nephrology 2026 Kidney Week. Data from phase 2 and interim trials covered lupus nephritis, membranous nephropathy and IgA nephropathy.
Why it matters
Glomerular diseases damage the kidneys' filtering units and can progress to kidney failure, so new treatment options are closely watched by nephrologists and patients. The results point to therapies that may produce faster responses or reach patients previously excluded from trials, though larger studies are still needed to confirm them.
In the phase 2 POSTERITY trial, 70% of obinutuzumab-treated adolescents with lupus nephritis reached complete renal response at week 76 versus 20% on placebo, while serious infections occurred in 30% versus 20%. Median time to response was 3 weeks with HLX79 plus rituximab compared with 11.1 weeks with rituximab alone, and further studies are needed to compare allogeneic and autologous CAR T-cell therapies.
The players
Brad Rovin
A nephrologist at Ohio State University Wexner Medical Center who presented updates on emerging glomerular disease therapies at Kidney Week 2026.
American Society of Nephrology
A professional medical society of kidney specialists that hosts the annual Kidney Week conference, the largest gathering of nephrology researchers and clinicians.
The details
Dr. Brad Rovin, a nephrologist at Ohio State University Wexner Medical Center in Columbus, presented the findings. HLX79, a glycan-editing therapy, was given with rituximab in primary membranous nephropathy, and obinutuzumab was given with mycophenolate and glucocorticoids in the POSTERITY trial. Interim PIONEER data evaluated atacicept in membranous nephropathy and IgA nephropathy cohorts, including patients historically excluded from studies.
Timeline
Week 24: HLX79 response was assessed in the membranous nephropathy trial.
Week 76: Complete renal response was assessed in the POSTERITY trial.
6 months: Complete renal response was assessed for allogeneic CAR T-cell therapy.
The Big Picture
The updated POSTERITY results extend the phase 2 trial's earlier findings on obinutuzumab in adolescent lupus nephritis by reporting outcomes at week 76. Alongside the HLX79 and PIONEER data, they show the field moving toward therapies that target specific immune or glycan pathways rather than relying solely on broad immunosuppression.
For people living with lupus nephritis or membranous nephropathy, these results point to treatments that may bring kidney responses sooner, though the trials reported infection risks that patients should review with their doctors. Patients with refractory disease may eventually have access to new cell-based options, but these remain investigational and are not yet available outside research settings.
The takeaway
Early trial data suggest new kidney disease therapies can work faster or in harder-to-treat patients, but infection risks and small sample sizes mean patients should discuss emerging options with their nephrologist before expecting them in routine care.
Further reading
For more on related conditions, see Diseases — General on Wisevoter.






